Point B, an employee-owned US management consultancy headquartered in Seattle, was recently named a top workplace in Boston, Arizona, and Texas.
The firm was recognized as a 2020 Best Place to Work by the Boston Business Journal, as an honoree in the extra small company category. The 79 selected companies were chosen based on survey responses by employees.
Point B was also named a Top Workplace in Arizona by publication AZ Central. The 2020 award was the third year that the firm was chosen as an employer of choice in the medium company category. Point B was specifically praised for its support of work-life balance, its company culture, and the benefits of its employee ownership model.
Rounding out the recent accolades, Point B was named the #6 Best Large Company to Work for in Texas by Best Companies Group and Texas Monthly. The award was based on a survey, employee questionnaire, and analysis conducted by Best Companies Group.
The 2020 award was the fourth consecutive year where Point B placed in the top 10 large employers in Texas. The ranking noted the company’s efforts in work-life balance, community involvement, and leadership development.
Point B has racked up numerous other employer accolades. Forbes previously named the company a Best Medium-Sized Workplace, a Best Workplace for Millennials, and a Best Workplace for Parents. The company has also been recognized as a top workplace by several other local publication rankings, including the Portland Business Journal, Seattle Business magazine, Charlotte Business Journal, Crain’s Chicago Business, and San Francisco Business Times.
Based in Seattle, Point B delivers professional services in strategy, organizational change, design and creative, data analytics, and real estate development. The firm has 800+ employees across more than a dozen office locations in the United States. Point B is part of the Nextcontinent network.
The firm in May launched a new Rapid Strategy Disruption Response offering to help clients deal with the ongoing challenges presented by Covid-19.